Prognostic Value of Completion Lymph Node Dissection on Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Meta-analysis

LANG Zhongliang; WANG Minggang

doi:10.3971/j.issn.1000-8578.2018.17.0955

Cancer Research on Prevention and Treatment > 2018 > 45(5): 311-315. > DOI: 10.3971/j.issn.1000-8578.2018.17.0955

LANG Zhongliang, WANG Minggang. Prognostic Value of Completion Lymph Node Dissection on Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 311-315. DOI: 10.3971/j.issn.1000-8578.2018.17.0955

Citation:

PDF (3394 KB)

Prognostic Value of Completion Lymph Node Dissection on Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Meta-analysis

LANG Zhongliang,
WANG Minggang^,

Department of Plastic Surgery, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China

More Information

Corresponding author:
WANG Minggang, E-mail: mgwang1105@sina.com
Received Date: October 12, 2017
Revised Date: January 08, 2018
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To assess the prognostic value of completion lymph node dissection on melanoma patients with positive sentinel lymph node biopsy.
Methods
We searched PubMed, Embase, Cochrane Library, CNKI, Wanfang and the reference trace for relevant literature. Meta-analysis was applied for patients' survival.
Results
A total of 10 clinical trials were included. There was no significant difference between the completion lymph node dissection group and the lymph node observation group in melanoma specific survival (HR: 0.99, 95%CI: 0.86-1.14, P=0.89), recurrence-free survival (HR: 0.89, 95%CI: 0.72-1.08, P=0.24) or distant metastasis-free survival (HR: 1.03, 95%CI: 0.89-1.20, P=0.71).
Conclusion
Completion lymph node dissection could not benefit the survival of melanoma patients with positive sentinel lymph node biopsy.
- Melanoma,
- Sentinel lymph node biopsy,
- Lymph node dissection,
- Prognosis,
- Meta-analysis

FullText(HTML)

References (25)

References

[1]	Santos-Juanes J, Fernandez-Vega I, Galache Osuna C, et al. Sentinel lymph node biopsy plus wide local excision vs. Wide location excision alone for primary cutaneous melanoma: A systematic review and meta-analysis[J]. J Eur Acad Dermatol Venereol, 2017, 31(2): 241-6. doi: 10.1111/jdv.2017.31.issue-2
[2]	Tejera-Vaquerizo A, Nagore E. Effect of time to sentinel lymph node biopsy on cutaneous melanoma survival: A matter of discussion[J]. Am J Surg, 2017, 213(1): 204-5. doi: 10.1016/j.amjsurg.2016.06.014
[3]	Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma[J]. Br J Dermatol, 2004, 151(2): 308-19. doi: 10.1111/bjd.2004.151.issue-2
[4]	Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma[J]. N Engl J Med, 2014, 370(7): 599-609. doi: 10.1056/NEJMoa1310460
[5]	National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Melanoma. Version 1. 2017[EB/OL]. Http://www.Nccn.Org/professionals/physician_gls/f_guidelines.Asp. Accessed 10 November 2016.
[6]	Kyrgidis A, Tzellos T, Mocellin S, et al. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma[J]. Cochrane Database Syst Rev, 2015, (5):CD010307. http://europepmc.org/abstract/MED/25978975
[7]	Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8: 16. doi: 10.1186/1745-6215-8-16
[8]	Smith VA, Cunningham JE, Lentsch EJ. Completion node dissection in patients with sentinel node-positive melanoma of the head and neck[J]. Otolaryngol Head Neck Surg, 2012, 146(4): 591-9. doi: 10.1177/0194599811432672
[9]	Lee DY, Lau BJ, Huynh KT, et al. Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma[J]. J Am Coll Surg, 2016, 223(1): 9-18. doi: 10.1016/j.jamcollsurg.2016.01.045
[10]	Satzger I, Meier A, Zapf A, et al. Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?[J]. Melanoma Res, 2014, 24(5): 454-61. doi: 10.1097/CMR.0000000000000081
[11]	Bamboat ZM, Konstantinidis IT, Kuk D, et al. Observation after a positive sentinel lymph node biopsy in patients with melanoma[J]. Ann Surg Oncol, 2014, 21(9): 3117-23. doi: 10.1245/s10434-014-3758-7
[12]	Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: A multi-institutional study[J]. Ann Surg Oncol, 2006, 13(6): 809-16. doi: 10.1245/ASO.2006.03.058
[13]	Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (decog-slt): A multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(6): 757-67. doi: 10.1016/S1470-2045(16)00141-8
[14]	van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection[J]. Br J Surg, 2012, 99(10): 1396-405. doi: 10.1002/bjs.v99.10
[15]	Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy[J]. Ann Surg Oncol, 2010, 17(2): 514-20. doi: 10.1245/s10434-009-0836-3
[16]	Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma[J]. N Engl J Med, 2017, 376(23): 2211-22. doi: 10.1056/NEJMoa1613210
[17]	van der Ploeg IM, Kroon BB, Antonini N, et al. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node?[J]. Ann Surg, 2009, 249(6): 1003-7. doi: 10.1097/SLA.0b013e3181a77eba
[18]	Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma[J]. Arch Surg, 1992, 127(4): 392-9. doi: 10.1001/archsurg.1992.01420040034005
[19]	Morton DL. Overview and update of the phase iii multicenter selective lymphadenectomy trials (mslt-i and mslt-ii) in melanoma[J]. Clin Exp Metastasis, 2012, 29(7): 699-706. doi: 10.1007/s10585-012-9503-3
[20]	Link J. Completion lymph node dissection in patients with melanoma and positive sentinel lymph node biopsy[J]. JAAPA, 2017, 30(7): 31-4. http://www.ncbi.nlm.nih.gov/pubmed/28644220
[21]	Sabel MS, Rice JD, Griffith KA, et al. Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy[J]. Ann Surg Oncol, 2012, 19(1): 287-93. doi: 10.1245/s10434-011-1979-6
[22]	Egger ME, Kimbrough CW, Stromberg AJ, et al. Melanoma patient-reported quality of life outcomes following sentinel lymph node biopsy, completion lymphadenectomy, and adjuvant interferon: Results from the sunbelt melanoma trial[J]. Ann Surg Oncol, 2016, 23(3): 1019-25. doi: 10.1245/s10434-015-5074-2
[23]	Nagaraja V, Eslick GD. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis[J]. Eur J Surg Oncol, 2013, 39(7): 669-80. doi: 10.1016/j.ejso.2013.02.022
[24]	van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients[J]. Eur J Cancer, 2014, 50(1): 111-20. doi: 10.1016/j.ejca.2013.08.023
[25]	Egger ME, Bower MR, Czyszczon IA, et al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma[J]. J Am Coll Surg, 2014, 218(4): 519-28. doi: 10.1016/j.jamcollsurg.2013.12.014

[1]	LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957
[2]	SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158
[3]	RAO Xionghui, LUO Hongliang, HUANG Jun, ZHU Zhengming. Prognostic and Clinicopathological Significance of PD-L1 Expression for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2019, 46(11): 1013-1021. DOI: 10.3971/j.issn.1000-8578.2019.19.0363
[4]	ZHANG Tingting, WANG Xiangyi, GUO Ziwei, DING Xiaosheng, LIANG Jun. Prognostic Significance of Platelet-lymphocyte Ratio in Hepatocellular Carcinoma Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 775-780. DOI: 10.3971/j.issn.1000-8578.2018.18.0151
[5]	CUI Gang, YAN Bin, TAO Yongguang. Effect of FDG-PET/CT in Diagnosis, Staging and Prognosis of Pancreatic Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 202-208. DOI: 10.3971/j.issn.1000-8578.2017.03.010
[6]	TAN Yi, LIU Yan, SONG Yuwei, CHEN Qiufang, TAN Guoqiang, GUI Xiujuan, LIN Shaoqiang. Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 783-788. DOI: 10.3971/j.issn.1000-8578.2016.09.011
[7]	TIAN Jinhui, LI Jinlong, GE Long, WANG Jing, ZHANG Mingxia, SHI Fangyu, WANG Xiaohu, ZHANG Hong. Diagnostic Value of PET/CT for Metastatic Lymph Nodes in Cervical Cancer Patients: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 270-276. DOI: 10.3971/j.issn.1000-8578.2015.03.013
[8]	Zheng, Wang Shuyi, Xiong Bin. Meta-analysis on Association of Circulating Tumor Cells with Prognosis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1139-1145. DOI: 10.3971/j.issn.1000-8578.2012.09.021
[9]	ZHENG Gang, WANG Shu-yi, XIONG Bin. Meta-analysis on Association of HER2-neu Expression with Prognosis in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(10): 1173-1177. DOI: 10.3971/j.issn.1000-8578.2011.10.021
[10]	QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025

Cited By

Cited by

Periodical cited type(1)

周宁，王虎明，张萱，李丽莉，徐杰，高玉骞. D-二聚体与淋巴细胞比值对B细胞淋巴瘤患者预后预测的临床价值研究. 标记免疫分析与临床. 2023(10): 1688-1694 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1878) PDF downloads (303) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Prognostic Value of Completion Lymph Node Dissection on Melanoma Patients with Positive Sentinel Lymph Node Biopsy: A Meta-analysis